Sandoz has landed a regional first with its launch of the Stelara (ustekinumab) biosimilar Pyzchiva in autoinjector form in Europe, putting it one step ahead of other players.
While the company has already launched Pyzchiva in the EU last year in different presentations, the autoinjector could offer a...
Welcome to Generics Bulletin
Create an account to read this article
Already a subscriber?